Key facts
- This page summarizes Stephen C. Glover's Form 4 filing for Ambrx Biopharma Inc..
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2023, 16:17.
Stephen C. Glover - 18 May 2023 Form 4 Insider Report for Ambrx Biopharma Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 18 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2023, 16:17:34 UTC
- Prior SEC filing
- 13 Dec 2022
- Next SEC filing
- 18 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sonja Nelson, Attorney-in-Fact for Stephen Glover
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen C. Glover filed Form 4 for Ambrx Biopharma Inc. on 09 Jun 2023.
Change
- Previous filing in this sequence was filed on 13 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMAM
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +85,000
- Change %
- Price
- $0.000000
- Shares after
- 85,000
- Date
- 07 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMAM
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 07 Jun 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 40,000
- Exercise price
- $1.96
- Footnotes
- F1, F3, F4
AMAM
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +17,500
- Change %
- Price
- $0.000000
- Shares after
- 17,500
- Date
- 18 May 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 17,500
- Exercise price
- $1.97
- Footnotes
- F1, F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer.
Footnote F2
Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting.
Footnote F3
The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS.
Footnote F4
The options vest on June 7, 2024.
Footnote F5
The options vested on June 6, 2023.